Clinical Trials Browser

Phase 2 × Neoplasm, Residual × Imatinib Mesylate × Clear all

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT00267085 2012-08-07

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Phase 2 Completed

11 enrolled 6 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual